Метаболический синдром и доброкачественная гиперплазия предстательной железы: единство патофизиологических механизмов и новые перспективы патогенетической терапии

1. Бернштейн Л.М. Антидиабетический бугуанид метформин и онкологическая заболеваемость. Сахарный диабет. 2010; 3: 3–6.
2. Корнеев И.А., Глазнева С.Ю. Уровень тестостерона и расстройства мочеиспускания у больных с доброкачественной гиперплазией предстательной железы. Мужское здоровье. Материалы IV Всероссийского конгресса. М., 2008; с. 49–50.
3. Назаров Т.Н. Диагностика и лечение возрастного андрогенного дефицита: Дис. … д-ра мед. наук. СПб., 2000.
4. Чупрына П.С., Деревянченко В.И., Щелков С.В. Доброкачественная гиперплазия простаты, осложненная ОЗМ, и уровень тестостерона крови. Мужское здоровье. Материалы IV Всероссийского конгресса. М., 2008; с. 66–7.
5. Шустер П.И. Возрастной андрогенный дефицит – один из ведущих этиологических факторов уролитиаза у мужчин. Мужское здоровье. Материалы IV Всероссийского конгресса. М., 2008; с. 37–8.
6. Albanes D, Weinstein SJ, Wright ME et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 2009; 101: 1272–9.
7. Alberti G. Introduction to the metabolic syndrome. Eur Heart J 2005; 7 (Suppl D): 3–5.
8. Alexandraki K, Piperi C, Kalofoutis C. Inflammatory process in type 2 diabetes: the role of cytokines. Ann N Y Acad Sci 2006; 1084: 89–117.
9. Ansari MA, Begum D, Islam F. Serum sex steroids, gonadotrophins and sex hormonebinding globulin in prostatic hyperplasia. Ann Saudi Med 2008; 28: 174–8.
10. Azadzoi KM, Babayan RK, Kozlowski R. Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol 2003; 170 (2 Pt 1): 659–63.
11. Azadzoi KM, Tarcan T, Siroky MB, Krane RJ. Atherosclerosis-induced chronic ischemia causes bladder fibrosis and non-compliance in the rabbit. J Urol 1999; 161: 1626–35.
12. Baron AD. Insulin resistance and vascular function. J Diabetes Complications 2002; 16: 92–102.
13. Niskanen L, Laaksonen DE, Punnonen K. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 2004; 6: 208–15.
14. Collin SM, Metcalfe C, Donovan J. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screendetected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int 2008; 102: 1400–6.
15. Cornu JN, Cussenot O, Haab F, Lukacs B. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol 2010; 58 (3): 450–6.
16. Demir O, Akgul K, Akar Z. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male 2009; 12: 29–34.
17. Oelke M, Bachmann A, Descazeaud A et al. EAU BHP Guidelines. EAU, 2010.
18. Fibbi B, Penna G, Morelli A. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010; 33: 475–88.
19. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002; 288: 1723–7.
20. Geiss LS, Pan L, Cadwell B. Changes in incidence of diabetes in U.S. adults, 1997–2003. Am J Prev Med 2006; 30: 371–7.
21. Golden SH, Robinson KA, Saldanha I. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009; 94: 1853–78.

22. Gorbachinsky I. Metabolic Syndrome and Urological Deseases. Rev Urol 2010; 12 (4): 157–80.
23. Grundy SM, Cleeman JI, Daniels SR. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–52.
24. Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology 2006; 68: 1198–205.
25. Haider A, Gooren LJ, Padungtod P, Saad F. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia 2009; 41: 7–13.
26. Hammarsten J, Högstedt B, Holthuis N. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998; 1: 157–62.
27. Ho CK, Nanda J, Chapman KE, Habib FK. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. J Endocrinol 2008; 197: 483–91.
28. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009; 2: 231–7.
29. Kalinchenko S, Vishnevsky EL, Koval AN. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male 2008; 11: 57–61.
30. Kalinchenko SY, Tishova YA, Mskhalaya GJ et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010; 3 (5): 602–12.
31. Karazindiyanoğğlu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male 2008; 11 (3): 146–9.
32. Knowler WC, Barrett-Connor E, Fowler SE et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
33. Koritsiadis G, Stravodimos K, Mitropoulos D. Androgens and bladder outlet obstruction: a correlation with pressure-flow variables in a preliminary study. BJU Int 2008; 101: 1542–6.
34. Kozlowski R, Kershen RT, Siroky MB. Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol 2001; 165: 1019–26.
35. Kupelian V, McVary KT, Kaplan SA. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol 2009; 182: 616–24 (discussion 624–5).
36. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986; 61: 1081–90.
37. Lee MJ, Fried SK. Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion. Am J Physiol Endocrinol Metab 2009; 296: 1230–8.
38. Leibson CL, O’Brien PC, Atkinson E. Relative contributions of incidence and survival to increasing prevalence of adult-onset diabetes mellitus: a population-based study. Am J Epidemiol 1997; 146: 12–22.
39. Low S, Chin MC, Deurenberg-Yap M. Review on epidemic of obesity. Ann Acad Med Singapore 2009; 38: 57–9.
40. Malik S, Wong ND, Franklin SS. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245–50.
41. Martin-Cordero L, Garcia JJ, Giraldo E. Influence of exercise on the circulating levels and macrophage production of IL-1beta and IFNgamma affected by metabolic syndrome: an obese Zucker rat experimental animal model. Eur J Appl Physiol 2009; 107: 535–43.
42. McVary K, Bautista OM, Kusek J. The association of lower urinary tract symptoms (LUTS) with sexual function in men participating in a clinical trial of medical therapy for benign prostatic hyperplasia. J Urol 2003; 169 (Suppl.): 322.
43. McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005; 174 (4 Pt 1): 1327–433.
44. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006; 97 (Suppl. 2): 23–8.
45. Michel MC, Heemann U, Schumacher H. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 2004; 172: 1390–3.
46. Mokdad AH, Ford ES, Bowman BA. Diabetes trends in the U.S.: 1990–1998. Diabetes Care 2000; 23: 1278–83.
47. Niskanen L, Laaksonen DE, Punnonen K. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 2004; 6: 208–15.
48. Oreste M, Giuseppe PG, Gianna P. Betweensubject variations of transition zone epithelial volume and serum PSA levels in men with benign prostatic hyperplasia. World J Urol 2010; 28: 379–83.
49. Ozden C, Ozdal OL, Urgancioglu G. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007; 51: 199–203 (discussion 204–6).
50. Park II, Zhang Q, Liu V. 17Beta-estradiol at low concentrations acts through distinct pathways in normal versus BPH-derived prostate stromal cells. Endocrinology 2009; 150: 4594–605.
51. Penna G, Fibbi B. Amuchastegui S. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate 2009; 69: 480–93.
52. Peters SL, Schmidt M, Michel MC. Rho kinase: a target for treating urinary bladder dysfunction? Trends Pharmacol Sci 2006; 27: 492–7.
53. Rees RW, Foxwell NA, Ralph DJ. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 2003; 170 (6 Pt 1): 2517–22.
54. Rhoden EL, Fornari A, Fuchs SC, Ribeiro EP. Evaluation of the association between lower urinary tract symptoms and erectile dysfunction, considering its multiple risk factors. J Sex Med 2008; 5 (11): 2662–8.
55. Robert G, Descazeaud A, Nicolaïew N. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 2009; 69: 1774–80.
56. Rohrmann S, de Marzo AM, Smith E. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005; 62: 27–33.
57. Rohrmanns S, Nelson WG, Rifai N. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology 2007; 69: 708–13.
58. Rustenbeck I. Desensitization of insulin secretion. Biochem Pharmacol 2002; 63: 1921–35.
59. Sauzeau V, Le Jeune H, Cario-Toumaniantz C. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 2000; 275: 21722–9.
60. Schatzl G, Brössner C, Schmid S. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology 2000; 55: 397–402.
61. Smith P, Rhodes NP, Ke Y, Foster CS. Upregulation of estrogen and androgen receptors modulate expression of FGF-2 and FGF-7 in human, cultured, prostatic stromal cells exposed to high concentrations of estradiol. Prostate Cancer Prostatic Dis 2002; 5: 105–10.
62. Srikanthan P, Karlamangla AS. Relative Muscle Mass Is Inversely Associated withInsulin Resistance and Prediabetes. Findings from The Third National Health and Nutrition Examination Survey. J Clin Endocrin Metab. First published ahead of print July 21, 2011 as doi:10.1210/jc.2011-0435.
63. Sturm R. Increases in clinically severe obesity in the United States, 1986–2000. Arch Intern Med 2003; 163: 2146–8.
64. Takahashi R, Nishimura J, Seki N. RhoA/Rho kinase-mediated Ca2+ sensitization in the contraction of human prostate. Neurourol Urodyn 2007; 26: 547–51.
65. Temml C, Obermayr R, Marszalek M. Are lower urinary tract symptoms influenced by metabolic syndrome? Urology 2009; 73: 544–8.
66. Termizy HM, Mafauzy M. Metabolic syndrome and its characteristics among obese patients attending an obesity clinic. Singapore Med J 2009; 50: 390–4.
67. Tomita K, Mizoue T, Matsumoto T. Lower urinary tract symptoms in relation to lifestyle and medical conditions in Japanese workers. Int J Urol 2009; 16: 493–8 (discussion 498).
68. Winter ML, Liehr JG. Possible mechanism of induction of benign prostatic hyperplasia by estradiol and dihydrotestosterone in dogs. Toxicol Appl Pharmacol 1996; 136: 211–9.
69. Yassin AA, El-Sakka AI, Saad F, Gooren LJ. Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia 2008; 40: 259–64.

1С.Ю.Калинченко, 2И.А.Тюзиков, 3Е.А.Греков, 1Л.О.Ворслов, 1А.М.Фомин, 1Ю.А.Тишова 

1. Кафедра эндокринологии ФПКМР ГБОУ ВПО РУДН, Москва; 
2. Медицинский центр диагностики и профилактики-Плюс, Ярославль;  
3. ФГБУ НИИ урологии Минздрава РФ, Москва